Search

Your search keyword '"Stelma F.F."' showing total 187 results
Start Over Author "Stelma F.F."
187 results on '"Stelma F.F."'

1. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Author

van der Valk, M., Geerlings, S.E., Goorhuis, A., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., van Duinen, M., van Eden, J., Hazenberg, A., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Jurriaans, S., Back, N.K.T., Zaaijer, H.L., Berkhout, B., Cornelissen, M.T.E., Schinkel, C.J., Wolthers, K.C., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., Ang, C.W., van Houdt, R., Jonges, M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., Buiting, A., Reuwer, A., Veenemans, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., van den Bersselaar, D.N.J., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Nellen, J., Brokking, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., Adams, A., van Erve, R., de Kruijf-van de Wiel, B.A.F.M., Keelan-Phaf, S., van de Ven, B., Buiting, A.G.M., Murck, J.L., de Vries-Sluijs, T.E.M.S., Bax, H.I., van Gorp, E.C.M., de Jong-Peltenburg, N.C., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Rokx, C., Schurink, C.A.M., Slobbe, L., Verbon, A., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., Boucher, C.A.B., Koopmans, M.P.G., van Kampen, J.J.A., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., van IJperen, J.M., Geilings, J., van Burgel, N.D., Leyten, E.M.S., van der Hut, G., Gelinck, L.B.S., Mollema, F., Davids-Veldhuis, S., Tearno, C., Wildenbeest, G.S., Heikens, E., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., Kraan, S., van Hulzen, A.G.W., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Kroon, F.P., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Roukens, A.H.E., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., den Hollander, J.G., Brouwer, C.J., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., El Moussaoui, R., Pogany, K., Pontesilli, O., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Schippers, J., Weijenberg-Maes, B., van Loo, I.H.M., Havenith, T.R.A., van Vonderen, M.G.A., Kampschreur, L.M., Faber, S., Steeman-Bouma, R., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Ruiter-Pronk, D., van Truijen-Oud, F.A., Cohen Stuart, J.W.T., Jansen, E.R., Hoogewerf, M., Rozemeijer, W., van der Reijden, W.A., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Blok, W.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Kok, M., Knapen, M., van der Meché, I.B., Mulder-Seeleman, E., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van Crevel, R., Dofferhoff, A.S.M., ter Hofstede, H.J.M., Hoogerwerf, J., Keuter, M., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F.F., Burger, D., Gisolf, E.H., Hassing, R.J., Claassen, M., ter Beest, G., van Bentum, P.H.M., Langebeek, N., Tiemessen, R., Swanink, C.M.A., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Bermon, N., Jansen, R., Herpers, B.L., Veenendaal, D., Verhagen, D.W.M., Lauw, F.N., van Broekhuizen, M.C., van Wijk, M., Bierman, W.F.W., Bakker, M., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Groot-de Jonge, H., van der Meulen, P.A., de Weerd, D.A., Niesters, H.G.M., van Leer-Buter, C.C., Knoester, M., Hoepelman, A.I.M., Arends, J.E., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Mudrikova, T., Oosterheert, J.J., Schadd, E.M., van Welzen, B.J., Aarsman, K., Griffioen-van Santen, B.M.G., de Kroon, I., van Berkel, M., van Rooijen, C.S.A.M., Schuurman, R., Verduyn-Lunel, F., Wensing, A.M.J., Reiss, P., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M., de Jong, A., Woudstra, T., Bergsma, D., Meijering, R., van de Sande, L., Rutkens, T., van der Vliet, S., de Groot, L., van den Akker, M., Bakker, Y., El Berkaoui, A., Bezemer, M., Brétin, N., Djoechro, E., Groters, M., Kruijne, E., Lelivelt, K.J., Lodewijk, C., Lucas, E., Munjishvili, L., Paling, F., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M., Schnörr, P., Scheigrond, A., Tuijn, E., Veenenberg, L., Visser, K.M., Witte, E.C., Smit, Colette, Boyd, Anders, Rijnders, Bart J A, van de Laar, Thijs J W, Leyten, Eliane M, Bierman, Wouter F, Brinkman, Kees, Claassen, Mark A A, den Hollander, Jan, Boerekamps, Anne, Newsum, Astrid M, Schinkel, Janke, Prins, Maria, Arends, Joop E, Op de Coul, Eline L M, van der Valk, Marc, and Reiss, Peter

Published
2021
Full Text
View/download PDF

3. Classical Borrelia Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study.

Author

Stelma, F.F., Berende, A., Hofstede, H.J.M. ter, Vrijmoeth, H.D., Vos, F.J., Kullberg, B.J., Stelma, F.F., Berende, A., Hofstede, H.J.M. ter, Vrijmoeth, H.D., Vos, F.J., and Kullberg, B.J.

Abstract

Contains fulltext : 293169.pdf (Publisher’s version ) (Open Access), OBJECTIVE: The diagnosis of Lyme borreliosis is based on two-tier testing using an ELISA and Western blot. About 5-10% of patients report persistent symptoms of unknown etiology after treatment, resulting in substantial difficulties in further diagnostic workup. This paper presents a study aimed at determining whether serology can differentiate between patients with persistent symptoms attributed to Lyme and other patients with Lyme borreliosis. METHODS: A retrospective cohort study included 162 samples from four subgroups: patients with persistent symptoms of Lyme (PSL), early Lyme borreliosis with erythema migrans (EM), patients tested in a general practitioner setting (GP), and healthy controls (HC). ELISA, Western blots, and multiplex assays from different manufacturers were used to determine inter-test variations in PSL and to compare reactivity against Borrelia-specific antigens among the groups. RESULTS: In comparing the IgG and IgM reactivity by Western blot, IgG was more often positive in the PSL group than in the GP group. The individual antigen reactivity was similar between the PSL and EM or GP groups. Inter-test agreement among the manufacturers was variable, and agreement was higher for IgG testing compared to IgM. CONCLUSIONS: Serological testing is unable to define the subgroup of patients with persistent symptoms attributed to Lyme borreliosis. Additionally, the current two-tier testing protocol shows a large variance among different manufacturers in these patients.

Published
2023

5. An International External Quality Assessment Scheme to Assess the Diagnostic Performance of Polymerase Chain Reaction Detection of Acanthamoeba Keratitis.

Author

Sarink, M.J., Koelewijn, R., Stelma, F.F., Kortbeek, T., Lieshout, L. van, Smit, P.W., Tielens, A.G.M., Hellemond, J.J. van, Sarink, M.J., Koelewijn, R., Stelma, F.F., Kortbeek, T., Lieshout, L. van, Smit, P.W., Tielens, A.G.M., and Hellemond, J.J. van

Abstract

Contains fulltext : 294545.pdf (Publisher’s version ) (Open Access), PURPOSE: The purpose of this study was to assess the variation in methods and to determine whether an External Quality Assessment Scheme (EQAS) for polymerase chain reaction (PCR) detection of Acanthamoeba keratitis is valuable for the diagnostic process. METHODS: A multicenter EQAS was introduced, covering 16 diagnostic laboratories. Using Acanthamoeba castellanii ATCC strain 30010, 3 sets of samples were prepared, containing different amounts of DNA, cysts, or trophozoites. Samples were masked and sent to the participants with instructions for use and a questionnaire concerning the applied methodologies. Special attention in this questionnaire was given to the used pretreatment methods to assess existing variations in these procedures. RESULTS: A large variation in the methodologies and substantial differences in the diagnostic performance were found between participants. In contrast to the DNA samples where all participants had a perfect score, several false negative results were reported for the samples containing cysts or trophozoites. Only 9 participants had an optimal score, whereas one participant reported all samples as negative, one participant reported failures due to inhibition, and the other 5 reported in total 7 false negative results. A clear correlation was noticed between the PCR detection rate and the number of cysts or trophozoites in the sample. CONCLUSIONS: The results indicate that a pretreatment procedure can be a risky step in PCR-based detections of Acanthamoeba , but it improves the sensitivity and reliability, especially of samples containing cysts. Therefore, participation in an EQAS is informative for routine diagnostic laboratories and can assist in improving the laboratory procedures used for the diagnosis of Acanthamoeba keratitis.

Published
2023

6. Lyme Borreliosis Serology: A Prospective Cohort Study of Forestry Service Workers in the Netherlands over 8 Years (2008 to 2016) of Follow-Up.

Author

Hofstede, H.J.M. ter, Haex, J., Belias, M., Oosting, M., Joosten, L.A.B., Stelma, F.F., Hofstede, H.J.M. ter, Haex, J., Belias, M., Oosting, M., Joosten, L.A.B., and Stelma, F.F.

Abstract

Item does not contain fulltext, There is little known about the dynamics within responses to Borrelia spp. upon repeated exposure to tick bites and the development of serological markers over time. Most studies have investigated antibody development in risk populations over a short period of time. Therefore, we aimed to study the dynamics of anti-Borrelia antibodies in forestry service workers over 8 years in association with tick bite exposure. METHODS: Blood samples from 106 forestry service workers originally included in the 200 Functional Genomics Project (Radboudumc, Nijmegen, the Netherlands) were followed for 8 years and tested annually for anti-Borrelia antibodies (ELISA and Western blot). IgG seroconversion was related to the number of tick bites in the previous year, which was obtained through annual questionnaires. The hazard ratio for Borrelia IgG seroconversion was calculated using Cox regression survival analysis and a logistic regression model, both adjusting for age, gender and smoking. RESULTS: Borrelia IgG seropositivity in the study population did not vary significantly between years and the average prevalence was 13.4%. Of the 27 subjects that underwent seroconversion during the study period, 22 reconverted from positive to negative. Eleven subjects seroconverted a second time. The total seroconversion rate per year (negative to positive) was 4.5%. Active smoking was associated with IgG seroconversion in the >5 tick bites group (p < 0.05). According to the two models used, the risks of IgG seroconversion in the >5 tick bites group were HR = 2.93 (p = 0.10) and OR = 3.36 (p < 0.0005). CONCLUSIONS: Borrelia IgG seroconversion in forestry service workers was significantly related to increasing tick bite exposure in a survival and logistic regression model adjusting for age, gender and smoking.

Published
2023

7. Children living with HIV in Europe: do migrants have worse treatment outcomes?

Author

Chappell, E., Vasconcelos, M. Kohns, Goodall, R.L., Galli, L., Goetghebuer, T., Noguera-Julian, A., Rodrigues, L.C., Scherpbier, H., Smit, C., Bamford, A., Crichton, S., Navarro, M.L., Ramos, J.T., Warszawski, J., Spolou, V., Chiappini, E., Venturini, E., Prata, F., Kahlert, C., Marczynska, M., Marques, L., Naver, L., Thorne, C, Gibb, D.M., Giaquinto, C., Henriet, S.S.V., Strik-Albers, M.A.W., Rahamat-Langendoen, J.C., Stelma, F.F., Burger, D.M., Judd, A., Collins, I.J., Chappell, E., Vasconcelos, M. Kohns, Goodall, R.L., Galli, L., Goetghebuer, T., Noguera-Julian, A., Rodrigues, L.C., Scherpbier, H., Smit, C., Bamford, A., Crichton, S., Navarro, M.L., Ramos, J.T., Warszawski, J., Spolou, V., Chiappini, E., Venturini, E., Prata, F., Kahlert, C., Marczynska, M., Marques, L., Naver, L., Thorne, C, Gibb, D.M., Giaquinto, C., Henriet, S.S.V., Strik-Albers, M.A.W., Rahamat-Langendoen, J.C., Stelma, F.F., Burger, D.M., Judd, A., and Collins, I.J.

Abstract

Item does not contain fulltext, OBJECTIVES: To assess the effect of migrant status on treatment outcomes among children living with HIV in Europe. METHODS: Children aged < 18 years at the start of antiretroviral therapy (ART) in European paediatric HIV observational cohorts where ≥ 5% of children were migrants (defined as born abroad) were included. Three outcomes were considered: (i) severe immunosuppression-for-age; (ii) viraemic viral load (≥ 400 copies/mL) at 1 year after ART initiation; and (iii) AIDS/death after ART initiation. The effect of migrant status was assessed using univariable and multivariable logistic and Cox models. RESULTS: Of 2620 children included across 12 European countries, 56% were migrants. At ART initiation, migrant children were older than domestic-born children (median 6.1 vs. 0.9 years, p < 0.001), with slightly higher proportions being severely immunocompromised (35% vs. 33%) and with active tuberculosis (2% vs. 1%), but a lower proportion with an AIDS diagnosis (14% vs. 19%) (all p < 0.001). At 1 year after beginning ART, a lower proportion of migrant children were viraemic (18% vs. 24%) but there was no difference in multivariable analysis (p = 0.702), and no difference in severe immunosuppression (p = 0.409). However, there was a trend towards higher risk of AIDS/death in migrant children (adjusted hazard ratio = 1.51, 95% confidence interval: 0.96-2.38, p = 0.072). CONCLUSIONS: After adjusting for characteristics at ART initiation, migrant children have virological and immunological outcomes at 1 year of ART that are comparable to those who are domestic-born, possibly indicating equity in access to healthcare in Europe. However, there was some evidence of a difference in AIDS-free survival, which warrants further monitoring.

Published
2022

8. The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study

Author

Hoeve-Bakker, B.J.A., Jonker, M., Brandenburg, A.H., Reijer, P.M. den, Stelma, F.F., Dam, A.P. Van, Gorkom, T. van, Kerkhof, K., Thijsen, S.F., Kremer, K., Hoeve-Bakker, B.J.A., Jonker, M., Brandenburg, A.H., Reijer, P.M. den, Stelma, F.F., Dam, A.P. Van, Gorkom, T. van, Kerkhof, K., Thijsen, S.F., and Kremer, K.

Abstract

Contains fulltext : 252108.pdf (Publisher’s version ) (Open Access), In this retrospective study, the performance of nine serological screening assays for Lyme borreliosis (LB) diagnostics was evaluated using a study population of LB cases and controls. Sera derived from 74 well-defined LB cases and 122 controls were included. The LB cases were diagnosed with erythema migrans (EM; n = 11), Lyme neuroborreliosis (LNB; n = 35), Lyme arthritis (LA; n = 20), or acrodermatitis chronica atrophicans (ACA; n = 8). Controls comprised 74 age- and gender-matched healthy individuals and 48 patients with other diseases with anticipated high rates of cross-reactivity. The assays under evaluation were selected based on a literature review and expected continued availability with CE marking under the new in vitro diagnostic regulation (European Union) 2017/746. The overall sensitivity (IgG and IgM results combined) among LB cases ranged between 54.5% (6 of 11) and 90.9% (10 of 11) for EM patients and between 97.1% (34 of 35) and 100% for patients with LNB, LA, and ACA. The positivity rate ranged between 8.1% (6 of 74) and 29.7% (22 of 74) among the healthy controls and between 22.9% (11 of 48) and 64.6% (31 of 48) among the cross-reactivity controls. The IgM results were more heterogeneous than the IgG and IgM/IgG results and did not contribute to the overall sensitivity but substantially increased the positivity rates among the controls. In conclusion, all evaluated Borrelia serological screening assays performed comparably with respect to early- and late-disseminated LB. The addition of an IgM assay to the screening of Borrelia-specific IgG antibodies had no added value for the diagnosis of Lyme borreliosis. IMPORTANCE Serology plays an important role in the diagnosis of Lyme borreliosis. Guidelines prescribe a two-tier testing algorithm in which a highly sensitive screening assay is used for screening and reactive sera are retested with an immunoblot to reduce false positivity rates. Recently, two commonly used screening assays were discontinued

Published
2022

9. A highly virulent variant of HIV-1 circulating in the Netherlands.

Author

Wymant, C., Bezemer, D., Blanquart, F., Ferretti, L., Gall, A., Hall, M., Golubchik, T., Bakker, M., Ong, S.H., Zhao, L., Bonsall, D., Cesare, M. de, MacIntyre-Cockett, G., Abeler-Dörner, L., Albert, J., Bannert, N., Fellay, J., Grabowski, M.K., Gunsenheimer-Bartmeyer, B., Günthard, H.F., Kivelä, P., Kouyos, R.D., Laeyendecker, O., Meyer, L., Porter, K., Ristola, M., Sighem, A. van, Berkhout, B., Kellam, P., Strik-Albers, Riet, Rahamat-Langendoen, J.C., Stelma, F.F., Burger, D.M., Crevel, R. van, Aerde, K.J. van, Dofferhoff, A.S.M., Henriet, S.S.V., Hofstede, H.J.M. ter, Hoogerwerf, J.J., Keuter, M., Richel, O., Reiss, P., Fraser, C., Wymant, C., Bezemer, D., Blanquart, F., Ferretti, L., Gall, A., Hall, M., Golubchik, T., Bakker, M., Ong, S.H., Zhao, L., Bonsall, D., Cesare, M. de, MacIntyre-Cockett, G., Abeler-Dörner, L., Albert, J., Bannert, N., Fellay, J., Grabowski, M.K., Gunsenheimer-Bartmeyer, B., Günthard, H.F., Kivelä, P., Kouyos, R.D., Laeyendecker, O., Meyer, L., Porter, K., Ristola, M., Sighem, A. van, Berkhout, B., Kellam, P., Strik-Albers, Riet, Rahamat-Langendoen, J.C., Stelma, F.F., Burger, D.M., Crevel, R. van, Aerde, K.J. van, Dofferhoff, A.S.M., Henriet, S.S.V., Hofstede, H.J.M. ter, Hoogerwerf, J.J., Keuter, M., Richel, O., Reiss, P., and Fraser, C.

Abstract

Item does not contain fulltext, We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log(10) increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.

Published
2022

11. Eindverslag pilot sneltesten en welzijn in het mbo en ho Nijmegen Ministerie OC&W

Author

Schilderman, J.B.A.M., Stelma, F.F., Wertheim, H.F.L., Kregting, J., and Sanders, J.M.

Subjects
Center for Religion and Contemporary Society (CRCS), Narrative, Cognition & Communication, Language & Communication
Abstract

Item does not contain fulltext Rapportage aan de minister van Onderwijs, Cultuur en Wetenschap (OCW)

Published
2021

12. Malaria diagnosis in a malaria non-endemic high-resource country: high variation of diagnostic strategy in clinical laboratories in the Netherlands

Author

Boonstra, M.B., Koelewijn, R., Brienen, E.A.T., Silvis, W., Stelma, F.F., Mank, T.G., Mulder, Bert, Lieshout, L. van, Hellemond, J.J. van, Boonstra, M.B., Koelewijn, R., Brienen, E.A.T., Silvis, W., Stelma, F.F., Mank, T.G., Mulder, Bert, Lieshout, L. van, and Hellemond, J.J. van

Abstract

Contains fulltext : 244037.pdf (Publisher’s version ) (Open Access), BACKGROUND: Microscopic examination of thick and thin blood films is the gold standard in current guidelines for the diagnosis of malaria, but guidelines do not uniformly agree on which combination of other methods should be used and when. METHODS: Three questionnaires were sent between March 2018 and September 2019 to laboratories subscribing to the external quality assessment scheme for the diagnosis of blood and intestinal parasites of the Dutch Foundation for Quality Assessment in Medical Laboratories in order to investigate how much variation in the laboratory diagnosis of malaria between different clinical laboratories is present in the Netherlands. RESULTS: The questionnaires were partially or fully completed by 67 of 77 (87%) laboratories. Only 9 laboratories reported 10 or more malaria positive patients per year. Most laboratories use a different diagnostic strategy, within office versus outside office hours depending on the screening assay result. Within office hours, 62.5% (35/56) of the responding laboratories perform an immunochromatographic test (ICT) in combination with microscopic examination of thick and thin blood films without additional examinations, such as Quantitative Buffy Coat and/or rtPCR analysis. Outside office hours 85.7% (48/56) of laboratories use an ICT as single screening assay and positive results are immediately confirmed by thick and thin blood films without additional examinations (89.6%, 43/48). In case of a negative ICT result outside office hours, 70.8% (34/48) of the laboratories perform microscopic examination of the thick film the next morning and 22.9% (11/48) confirm the negative ICT result immediately. Furthermore, substantial differences were found in the microscopic examinations of thick and thin blood films; the staining, theoretical sensitivity of the thick film and determination of parasitaemia. CONCLUSIONS: This study demonstrated a remarkably high variation between laboratories in both their diagnostic strategy as

Published
2021

13. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands

Author

Boerekamps, A., Newsum, A.M., Smit, C., Arends, J.E., Richter, C., Reiss, P., Rijnders, B.J.A., Crevel, R. van, Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Hoogerwerf, J.J., Grintjes-Huisman, K.J.T., Rahamat-Langendoen, J.C., Stelma, F.F., Burger, D.M., Brinkman, K., Valk, M. van der, Internal Medicine, Medical Microbiology & Infectious Diseases, Rehabilitation Medicine, Virology, Internal medicine, APH - Aging & Later Life, Pediatric surgery, Anatomy and neurosciences, Medical Microbiology and Infection Prevention, Amsterdam Movement Sciences - Rehabilitation & Development, AII - Infectious diseases, CCA - Cancer Treatment and quality of life, ACS - Diabetes & metabolism, AGEM - Digestive immunity, CCA - Cancer biology and immunology, Amsterdam Reproduction & Development (AR&D), and Chemical Biology

Subjects
Microbiology (medical), Male, Adult, medicine.medical_specialty, Hepatitis C virus, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Human immunodeficiency virus (HIV), HIV Infections/drug therapy, medicine.disease_cause, DIRECT ACTING ANTIVIRALS, Direct-acting antivirals, SDG 3 – Goede gezondheid en welzijn, Chronic/drug therapy, Coinfection/drug therapy, Health Services Accessibility, Men who have sex with men, Cohort Studies, 03 medical and health sciences, Sexual and Gender Minorities, 0302 clinical medicine, Hepatitis C, Chronic/drug therapy, SDG 3 - Good Health and Well-being, Internal medicine, Treatment uptake, medicine, Journal Article, Humans, 030212 general & internal medicine, Homosexuality, Male, Netherlands, Antiviral Agents/therapeutic use, business.industry, virus diseases, Hepatitis C, Homosexuality, Middle Aged, medicine.disease, HIV/HCV coinfection, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Treatment Outcome, Cohort, 030211 gastroenterology & hepatology, Female, business, Cohort study
Abstract

Background: The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV.Methods: Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response.Results: Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa-based regimen had failed in 54.Conclusions: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.

Published
2018
Full Text
View/download PDF

14. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Author

Smit, Colette, primary, Boyd, Anders, additional, Rijnders, Bart J A, additional, van de Laar, Thijs J W, additional, Leyten, Eliane M, additional, Bierman, Wouter F, additional, Brinkman, Kees, additional, Claassen, Mark A A, additional, den Hollander, Jan, additional, Boerekamps, Anne, additional, Newsum, Astrid M, additional, Schinkel, Janke, additional, Prins, Maria, additional, Arends, Joop E, additional, Op de Coul, Eline L M, additional, van der Valk, Marc, additional, Reiss, Peter, additional, van der Valk, M., additional, Geerlings, S.E., additional, Goorhuis, A., additional, Hovius, J.W., additional, Lempkes, B., additional, Nellen, F.J.B., additional, van der Poll, T., additional, Prins, J.M., additional, van Vugt, M., additional, Wiersinga, W.J., additional, Wit, F.W.M.N., additional, van Duinen, M., additional, van Eden, J., additional, Hazenberg, A., additional, van Hes, A.M.H., additional, Pijnappel, F.J.J., additional, Smalhout, S.Y., additional, Weijsenfeld, A.M., additional, Jurriaans, S., additional, Back, N.K.T., additional, Zaaijer, H.L., additional, Berkhout, B., additional, Cornelissen, M.T.E., additional, Schinkel, C.J., additional, Wolthers, K.C., additional, Peters, E.J.G., additional, van Agtmael, M.A., additional, Autar, R.S., additional, Bomers, M., additional, Sigaloff, K.C.E., additional, Heitmuller, M., additional, Laan, L.M., additional, Ang, C.W., additional, van Houdt, R., additional, Jonges, M., additional, van den Berge, M., additional, Stegeman, A., additional, Baas, S., additional, Hage de Looff, L., additional, Buiting, A., additional, Reuwer, A., additional, Veenemans, J., additional, Wintermans, B., additional, Pronk, M.J.H., additional, Ammerlaan, H.S.M., additional, van den Bersselaar, D.N.J., additional, de Munnik, E.S., additional, Deiman, B., additional, Jansz, A.R., additional, Scharnhorst, V., additional, Tjhie, J., additional, Wegdam, M.C.A., additional, van Eeden, A., additional, Nellen, J., additional, Brokking, W., additional, Elsenburg, L.J.M., additional, Nobel, H., additional, van Kasteren, M.E.E., additional, Berrevoets, M.A.H., additional, Brouwer, A.E., additional, Adams, A., additional, van Erve, R., additional, de Kruijf-van de Wiel, B.A.F.M., additional, Keelan-Phaf, S., additional, van de Ven, B., additional, Buiting, A.G.M., additional, Murck, J.L., additional, de Vries-Sluijs, T.E.M.S., additional, Bax, H.I., additional, van Gorp, E.C.M., additional, de Jong-Peltenburg, N.C., additional, de Mendonça Melo, M., additional, van Nood, E., additional, Nouwen, J.L., additional, Rijnders, B.J.A., additional, Rokx, C., additional, Schurink, C.A.M., additional, Slobbe, L., additional, Verbon, A., additional, Bassant, N., additional, van Beek, J.E.A., additional, Vriesde, M., additional, van Zonneveld, L.M., additional, de Groot, J., additional, Boucher, C.A.B., additional, Koopmans, M.P.G., additional, van Kampen, J.J.A., additional, Branger, J., additional, Douma, R.A., additional, Cents-Bosma, A.S., additional, Duijf-van de Ven, C.J.H.M., additional, Schippers, E.F., additional, van Nieuwkoop, C., additional, van IJperen, J.M., additional, Geilings, J., additional, van Burgel, N.D., additional, Leyten, E.M.S., additional, van der Hut, G., additional, Gelinck, L.B.S., additional, Mollema, F., additional, Davids-Veldhuis, S., additional, Tearno, C., additional, Wildenbeest, G.S., additional, Heikens, E., additional, Groeneveld, P.H.P., additional, Bouwhuis, J.W., additional, Lammers, A.J.J., additional, Kraan, S., additional, van Hulzen, A.G.W., additional, Kruiper, M.S.M., additional, van der Bliek, G.L., additional, Bor, P.C.J., additional, Debast, S.B., additional, Wagenvoort, G.H.J., additional, Kroon, F.P., additional, de Boer, M.G.J., additional, Jolink, H., additional, Lambregts, M.M.C., additional, Roukens, A.H.E., additional, Scheper, H., additional, Dorama, W., additional, van Holten, N., additional, Claas, E.C.J., additional, Wessels, E., additional, den Hollander, J.G., additional, Brouwer, C.J., additional, Smit, J.V., additional, Struik-Kalkman, D., additional, van Niekerk, T., additional, El Moussaoui, R., additional, Pogany, K., additional, Pontesilli, O., additional, Lowe, S.H., additional, Oude Lashof, A.M.L., additional, Posthouwer, D., additional, van Wolfswinkel, M.E., additional, Ackens, R.P., additional, Burgers, K., additional, Schippers, J., additional, Weijenberg-Maes, B., additional, van Loo, I.H.M., additional, Havenith, T.R.A., additional, van Vonderen, M.G.A., additional, Kampschreur, L.M., additional, Faber, S., additional, Steeman-Bouma, R., additional, Al Moujahid, A., additional, Kootstra, G.J., additional, Delsing, C.E., additional, van der Burg-van de Plas, M., additional, Scheiberlich, L., additional, Kortmann, W., additional, van Twillert, G., additional, Renckens, R., additional, Ruiter-Pronk, D., additional, van Truijen-Oud, F.A., additional, Cohen Stuart, J.W.T., additional, Jansen, E.R., additional, Hoogewerf, M., additional, Rozemeijer, W., additional, van der Reijden, W.A., additional, Sinnige, J.C., additional, Brinkman, K., additional, van den Berk, G.E.L., additional, Blok, W.L., additional, Lettinga, K.D., additional, de Regt, M., additional, Schouten, W.E.M., additional, Stalenhoef, J.E., additional, Veenstra, J., additional, Vrouenraets, S.M.E., additional, Blaauw, H., additional, Geerders, G.F., additional, Kleene, M.J., additional, Kok, M., additional, Knapen, M., additional, van der Meché, I.B., additional, Mulder-Seeleman, E., additional, Toonen, A.J.M., additional, Wijnands, S., additional, Wttewaal, E., additional, Kwa, D., additional, van Crevel, R., additional, Dofferhoff, A.S.M., additional, ter Hofstede, H.J.M., additional, Hoogerwerf, J., additional, Keuter, M., additional, Richel, O., additional, Albers, M., additional, Grintjes-Huisman, K.J.T., additional, de Haan, M., additional, Marneef, M., additional, Strik-Albers, R., additional, Rahamat-Langendoen, J., additional, Stelma, F.F., additional, Burger, D., additional, Gisolf, E.H., additional, Hassing, R.J., additional, Claassen, M., additional, ter Beest, G., additional, van Bentum, P.H.M., additional, Langebeek, N., additional, Tiemessen, R., additional, Swanink, C.M.A., additional, van Lelyveld, S.F.L., additional, Soetekouw, R., additional, van der Prijt, L.M.M., additional, van der Swaluw, J., additional, Bermon, N., additional, Jansen, R., additional, Herpers, B.L., additional, Veenendaal, D., additional, Verhagen, D.W.M., additional, Lauw, F.N., additional, van Broekhuizen, M.C., additional, van Wijk, M., additional, Bierman, W.F.W., additional, Bakker, M., additional, Kleinnijenhuis, J., additional, Kloeze, E., additional, Middel, A., additional, Postma, D.F., additional, Stienstra, Y., additional, Wouthuyzen-Bakker, M., additional, Boonstra, A., additional, de Groot-de Jonge, H., additional, van der Meulen, P.A., additional, de Weerd, D.A., additional, Niesters, H.G.M., additional, van Leer-Buter, C.C., additional, Knoester, M., additional, Hoepelman, A.I.M., additional, Arends, J.E., additional, Barth, R.E., additional, Bruns, A.H.W., additional, Ellerbroek, P.M., additional, Mudrikova, T., additional, Oosterheert, J.J., additional, Schadd, E.M., additional, van Welzen, B.J., additional, Aarsman, K., additional, Griffioen-van Santen, B.M.G., additional, de Kroon, I., additional, van Berkel, M., additional, van Rooijen, C.S.A.M., additional, Schuurman, R., additional, Verduyn-Lunel, F., additional, Wensing, A.M.J., additional, Reiss, P., additional, Zaheri, S., additional, Boyd, A.C., additional, Bezemer, D.O., additional, van Sighem, A.I., additional, Smit, C., additional, Hillebregt, M., additional, de Jong, A., additional, Woudstra, T., additional, Bergsma, D., additional, Meijering, R., additional, van de Sande, L., additional, Rutkens, T., additional, van der Vliet, S., additional, de Groot, L., additional, van den Akker, M., additional, Bakker, Y., additional, El Berkaoui, A., additional, Bezemer, M., additional, Brétin, N., additional, Djoechro, E., additional, Groters, M., additional, Kruijne, E., additional, Lelivelt, K.J., additional, Lodewijk, C., additional, Lucas, E., additional, Munjishvili, L., additional, Paling, F., additional, Peeck, B., additional, Ree, C., additional, Regtop, R., additional, Ruijs, Y., additional, Schoorl, M., additional, Schnörr, P., additional, Scheigrond, A., additional, Tuijn, E., additional, Veenenberg, L., additional, Visser, K.M., additional, and Witte, E.C., additional

Published
2021
Full Text
View/download PDF

15. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study.

Author

Chappell, E., Riordan, A., Jourdain, G., Soriano-Arandes, A., Ene, L., Scherpbier, H.J., Warszawski, J., Henriet, S.S.V., Flier, M. van der, Aerde, K.J. van, Albers, M.A., Rahamat-Langendoen, J.C., Stelma, F.F., Nardone, A., Thorne, C, Chappell, E., Riordan, A., Jourdain, G., Soriano-Arandes, A., Ene, L., Scherpbier, H.J., Warszawski, J., Henriet, S.S.V., Flier, M. van der, Aerde, K.J. van, Albers, M.A., Rahamat-Langendoen, J.C., Stelma, F.F., Nardone, A., and Thorne, C

Abstract

Contains fulltext : 217715.pdf (Publisher’s version ) (Open Access)

Published
2020

16. Therapie van parasitaire infecties in nederland

Author

Stelma, F.F., Hellemond, J. van, Genderen, P. van, Gool, T. van, Hekker, T., Kortbeek, T., Mank, T., Mulder, B., Visser, L de, and Sauerwein, R.W.

Subjects
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]
Abstract

Item does not contain fulltext

Published
2017

17. Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV

Author

Zoest, R.A. van, Law, M., Sabin, C.A., Vaartjes, I., Valk, M. van der, Arends, J.E., Reiss, P., Wit, F.W., Geerlings, S.E., Godfried, M.H., Goorhuis, A., Hovius, J.W., Kuijpers, T.W., Nellen, F.J.B., Poll, D.T. van der, Prins, J.M., Vugt, H.J.M. van, Wiersinga, W.J., Wit, F.W.M.N., Duinen, M. van, Eden, J. van, Hes, A.M.H. van, Pijnappel, F.J.J., Weijsenfeld, A.M., Jurriaans, S., Back, N.K.T., Zaaijer, H.L., Berkhout, B., Cornelissen, M.T.E., Schinkel, C.J., Wolthers, K.C., Peters, E.J.G., Agtmael, M.A. van, Bomers, M., Heitmuller, M., Laan, L.M., Ang, C.W., Houdt, R. van, Pettersson, A.M., Vandenbroucke-Grauls, C.M.J.E., Berge, M. van den, Stegeman, A., Baas, S., Looff, L.H. de, Wintermans, B., Veenemans, J., Pronk, M.J.H., Ammerlaan, H.S.M., Munnik, E.S. de, Jansz, A.R., Tjhie, J., Wegdam, M.C.A., Deiman, B., Scharnhorst, V., Eeden, A. van, Brokking, W., Groot, M., Elsenburg, L.J.M., Damen, M., Kwa, I.S., Kasteren, M.E.E. van, Brouwer, A.E., Erve, R. van, Kruijf-van de Wiel, B.A.F.M. de, Ven, B. van de, Buiting, A.G.M., Kabel, P.J., Versteeg, D., Ende, M.E. van der, Bax, H.I., Gorp, E.C.M. van, Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Verbon, A., Vries-Sluijs, T.E.M.S. de, Jong-Peltenburg, N.C. de, Bassant, N., Beek, J.E.A. van, Vriesde, M., Zonneveld, L.M. van, Berg-Cameron, H.J. van den, Groot, J. de, Zeeuw-de Man, M. de, Boucher, C.A.B., Koopmans, M.P.G., Kampen, J.J.A. van, Pas, S.D., Branger, J., Douma, R.A., Duijf-van de Ven, C.J.H.M., Schippers, E.F., Nieuwkoop, C. van, IJperen, J.M. van, Geilings, J., Hut, G. van der, Burgel, N.D. van, Leyten, E.M.S., Gelinck, L.B.S., Davids-Veldhuis, S., Hartingsveld, A.Y. van, Meerkerk, C., Wildenbeest, G.S., Heikens, E., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., Kraan, S., Hulzen, A.G.W. van, Kruiper, M.S.M., Bliek, G.L. van der, Bor, P.C.J., Bloembergen, P., Wolfhagen, M.J.H.M., Ruijs, G.J.H.M., Kroon, F.P., Boer, M.G.J. de, Scheper, H., Jolink, H., Dorama, W., Holten, N. van, Claas, E.C.J., Wessels, E., Hollander, J.G. den, Pogany, K., Roukens, A., Kastelijns, M., Smit, J.V., Smit, E., Struik-Kalkman, D., Tearno, C., Niekerk, T. van, Pontesilli, O., Lowe, S.H., Lashof, A.M.L.O., Posthouwer, D., Ackens, R.P., Burgers, K., Schippers, J., Weijenberg-Maes, B., Loo, I.H.M. van, Havenith, T.R.A., Mulder, J.W., Vrouenraets, S.M.E., Lauw, F.N., Broekhuizen, M.C. van, Vlasblom, D.J., Smits, P.H.M., Weijer, S., Moussaoui, R. el, Bosma, A.S., Vonderen, M.G.A. van, Kampschreur, L.M., Dijkstra, K., Faber, S., Weel, J., Kootstra, G.J., Delsing, C.E., Burg-van de Plas, M. van der, Heins, H., Kortmann, W., Twillert, G. van, Renckens, R., Ruiter-Pronk, D., Truijen-Oud, F.A. van, Stuart, J.W.T.C., IJzerman, E.P., Jansen, R., Reijden, W.A. van der, Brinkman, K., Berk, G.E.L. van den, Blok, W.L., Frissen, P.H.J., Lettinga, K.D., Schouten, W.E.M., Veenstra, J., Brouwer, C.J., Geerders, G.F., Hoeksema, K., Kleene, M.J., Meche, I.B. van der, Spelbrink, M., Toonen, A.J.M., Wijnands, S., Kwa, D., Regez, R., Crevel, R. van, Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Hoogerwerf, J., Grintjes-Huisman, K.J.T., Haan, M. de, Marneef, M., Rahamat-Langendoen, J., Stelma, F.F., Burger, D., Gisolf, E.H., Hassing, R.J., Claassen, M., Beest, G. ter, Bentum, P.H.M. van, Langebeek, N., Tiemessen, R., Swanink, C.M.A., Lelyveld, S.F.L. van, Soetekouw, R., Prijt, L.M.M. van der, Swaluw, J. van der, Bermon, N., Herpers, B.L., Veenendaal, D., Verhagen, D.W.M., Wijk, M. van, Bierman, W.F.W., Bakker, M., Kleinnijenhuis, J., Kloeze, E., Stienstra, Y., Wilting, K.R., Wouthuyzen-Bakker, M., Boonstra, A., Meulen, P.A. van der, Weerd, D.A. de, Niesters, H.G.M., Leer-Buter, C.C. van, Knoester, M., Hoepelman, A.I.M., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Mudrikova, T., Oosterheert, J.J., Schadd, E.M., Wassenberg, M.W.M., Zoelen, M.A.D. van, Aarsman, K., Elst-Laurijssen, D.H., Rozemeijer, Graduate School, AII - Infectious diseases, APH - Aging & Later Life, Infectious diseases, Global Health, APH - Digital Health, APH - Personalized Medicine, APH - Global Health, Microbes in Health and Disease (MHD), Neurochirurgie, RS: MHeNs - R3 - Neuroscience, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), RS: CAPHRI - R4 - Health Inequities and Societal Participation, Internal medicine, Pediatric surgery, Amsterdam Movement Sciences - Rehabilitation & Development, ACS - Diabetes & metabolism, AGEM - Digestive immunity, Medical Microbiology and Infection Prevention, Amsterdam Reproduction & Development (AR&D), Internal Medicine, Virology, and Medical Microbiology & Infectious Diseases

Subjects
Male, Heart disease, Human immunodeficiency virus (HIV), risk prediction algorithms, Blood Pressure, HIV Infections, Disease, 030312 virology, medicine.disease_cause, SUBCLINICAL ATHEROSCLEROSIS, Risk Factors, cardiovascular disease, FRAMINGHAM, Pharmacology (medical), Netherlands, 0303 health sciences, INFECTED PATIENTS, Framingham Risk Score, Middle Aged, Prediction algorithms, Cholesterol, Infectious Diseases, Anti-Retroviral Agents, Cardiovascular Diseases, HUMAN-IMMUNODEFICIENCY-VIRUS, Female, Risk assessment, Algorithms, Adult, Anti-HIV Agents, CARDIOLOGY/AMERICAN HEART ASSOCIATION, HEART-DISEASE, AMERICAN-COLLEGE, DATA-COLLECTION, Risk Assessment, EVENTS, 03 medical and health sciences, SDG 3 - Good Health and Well-being, INFLAMMATION, Environmental health, SCORE, medicine, Humans, Propensity Score, business.industry, HIV, medicine.disease, CD4 Lymphocyte Count, MYOCARDIAL-INFARCTION, Propensity score matching, Disease risk, business
Abstract

Background: People living with HIV (PLWH) experience a higher cardiovascular disease (CVD) risk. Yet, traditional algorithms are often used to estimate CVD risk. We evaluated the performance of 4 commonly used algorithms.Setting: The Netherlands.Methods: We used data from 16,070 PLWH aged > 18 years, who were in care between 2000 and 2016, had no pre-existing CVD, had initiated first combination antiretroviral therapy >1 year ago, and had available data on CD4 count, smoking status, cholesterol, and blood pressure. Predictive performance of 4 algorithms [Data Collection on Adverse Effects of Anti-HIV Drugs Study (D: A: D); Systematic COronary Risk Evaluation adjusted for national data (SCORE-NL); Framingham CVD Risk Score (FRS); and American College of Cardiology and American Heart Association Pooled Cohort Equations (PCE)] was evaluated using a Kaplan-Meier approach. Model discrimination was assessed using Harrell's C-statistic. Calibration was assessed using observed-versusexpected ratios, calibration plots, and Greenwood-Nam-D'Agostino goodness-of-fit tests.Results: All algorithms showed acceptable discrimination (Harrell's C-statistic 0.73-0.79). On a population level, D: A: D, SCORE-NL, and PCE slightly underestimated, whereas FRS slightly overestimated CVD risk (observed-versus-expected ratios 1.35, 1.38, 1.14, and 0.92, respectively). D: A: D, FRS, and PCE best fitted our data but still yielded a statistically significant lack of fit (Greenwood-Nam-D'Agostino chi(2) ranged from 24.57 to 34.22, P Conclusions: All algorithms perform reasonably well in PLWH, with SCORE-NL performing poorest. Prediction algorithms are useful for clinical practice, but clinicians should be aware of their limitations (ie, lack of fit and slight underestimation of CVD risk in low-risk groups).

Published
2019
Full Text
View/download PDF

18. Harmonization of PCR-based detection of intestinal pathogens: experiences from the Dutch external quality assessment scheme on molecular diagnosis of protozoa in stool samples

Author

Schuurs, Theo A., Koelewijn, R., Brienen, E.A.T., Kortbeek, T., Mank, T., Mulder, B., Stelma, F.F., Lieshout, L. van, Hellemond, J. van, Schuurs, Theo A., Koelewijn, R., Brienen, E.A.T., Kortbeek, T., Mank, T., Mulder, B., Stelma, F.F., Lieshout, L. van, and Hellemond, J. van

Abstract

Item does not contain fulltext

Published
2018

19. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study

Author

Hatleberg, C.I., Ryom, L., El-Sadr, W., Mocroft, A., Reiss, P., Wit, S. de, Dabis, F., Pradier, C., Monforte, A., Kovari, H., Law, M., Koopmans, P.P., Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Crevel, R. van, Albers, M.A., Bosch, M.E.W., Grintjes-Huisman, K.J.T., Zomer, B.J., Stelma, F.F., Rahamat-Langendoen, J.C., Burger, D.M., Lundgren, J.D., Sabin, C.A., Hatleberg, C.I., Ryom, L., El-Sadr, W., Mocroft, A., Reiss, P., Wit, S. de, Dabis, F., Pradier, C., Monforte, A., Kovari, H., Law, M., Koopmans, P.P., Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Crevel, R. van, Albers, M.A., Bosch, M.E.W., Grintjes-Huisman, K.J.T., Zomer, B.J., Stelma, F.F., Rahamat-Langendoen, J.C., Burger, D.M., Lundgren, J.D., and Sabin, C.A.

Abstract

Contains fulltext : 196903.pdf (publisher's version ) (Open Access)

Published
2018

20. High treatment uptake in human immunodeficiency virus/ hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands

Author

Boerekamps, A. (Anne), Newsum, A.M. (Astrid M.), Smit, C. (Colette), Arends, J.E. (Joop), Richter, C. (Clemens), Reiss, P. (Peter), Rijnders, B.J.A. (Bart), Brinkman, K. (Kees), Valk, M. (Marc) van der, Geerlings, S.E. (Suzanne), Godfried, M.H., Goorhuis, A. (Abraham), Hovius, J.W.R. (Joppe), Meer, J.T.M. (J. T M) van der, Kuijpers, T.W. (Taco W.), Nellen, F.J.B. (F. J B), Van Der Poll, D.T. (D. T.), Prins, J.M. (Jan), Van Vugt, H.J.M. (H. J.M.), Wiersinga, W.J. (W. J.), Wit, F.W.N.M. (Ferdinand), Van Duinen, M. (M.), Van Eden, J., Van Hes, A.M.H., Mutschelknauss, M., Nobel, H.E., Pijnappel, F.J.J., Weijsenfeld, A.M., Jurriaans, S. (Suzanne), Back, N. (Nicole), Zaaijer, H.L. (Hans), Berkhout, B. (Ben), Cornelissen, M. (Marion), Schinkel, C.J., Wolthers, K.C. (Katja), Van Den Berge, M., Stegeman, A., Baas, S., Hage De Looff, L. (L.), Wintermans, B. (B.), Veenemans, J. (J.), Pronk, M.J.H. (Marjolijn), Ammerlaan, H.S.M. (Heidi), De Munnik, E.S., Jansz, A.R. (A. R.), Tjhie, J. (J.), Wegdam, M.C.A., Deiman, B. (B.), Scharnhorst, V., Eeden, A. (Arne) van, Brokking, W. (W.), Groot, M.M. (Marieke), Elsenburg, L.J.M. (L. J.M.), Damen, M. (M.), Kwa, I.S., Kasteren, M.E.E. (Marjo) van, Brouwer, A.E., Van Erve, R. (R.), De Kruijf-Van De Wiel, B.A.F.M. (B. A.F.M.), Keelan-Pfaf, S. (S.), Van Der Ven, B. (B.), Van Der Ven, B., Buiting, A.G.M. (Anton), Kabel, P.J. (P. J.), Versteeg, D., Ende, M.E. (Marchina) van der, Bax, H.I. (Hannelore), Gorp, E.C.M. (Eric) van, Nouwen, J.L. (Jan), Schurink, C.A.M. (Carolina), Verbon, A. (Annelies), Vriessluijs, T.E.M.S. (Theodora) de, De Jong-Peltenburg, N.C. (N. C.), Bassant, N., Van Beek, J.E.A., Vriesde, M., van Zonneveld, L. (Laura), Van Den Berg-Cameron, H.J., Groot, J.C. (Jan Cees) de, De Zeeuw-De Man, M., Boucher, C.A.B. (Charles), Koopmans D.V.M., M.P.G. (Marion), Kampen, J.J.A. (Jeroen) van, Pas, S.D. (Suzan), Branger, J., Rijkeboer-Mes, A. (A.), Duijf-Van De Ven, C.J.H.M., Schippers, E.F. (E. F.), Nieuwkoop, C. (Cees) van, Van IJperen, J.M. (J. M.), Geilings, J. (J.), Van Der Hut, G., Burgel, N.D. (Nathalie ) van, Leyten, E.M.S. (Eliane), Gelinck, L.B.S. (Luc), Van Hartingsveld, A.Y. (A. Y.), Meerkerk, C., Wildenbeest, G.S., Heikens, E. (E.), Groeneveld, P.H.P. (P. H.P.), Bouwhuis, J.W. (Jolande), Lammers, A.J.J. (A. J.J.), Kraan, S. (S.), Van Hulzen, A.G.W., Van Der Bliek, G.L. (G. L.), Bor, P.C.J., Bloembergen, P. (Peter), Wolfhagen, M.J.H.M., Ruijs, G. (G.), Kroon, F.P. (F. P.), Boer, M.G.J. (Mark) de, Scheper, H. (H.), Jolink, A. (Albert), Vollaard, A. (Albert), Dorama, W. (Willemien), Van Holten, N. (N.), Claas, E.C.J. (Eric), Wessels, E. (E.), Hollander, J.G. (Jan) den, Pogány, K. (Katalin), Roukens, A. (A.), Kastelijns, M. (M.), Smit, J.V., Smit, E., Struik-Kalkman, D. (D.), Tearno, C. (C.), Van Niekerk, T., Pontesilli, O. (Oscar), Lowe, S.H. (S. H.), Oude Lashof, A. (A.), Posthouwer, D. (Dirk), Ackens, R.P. (R. P.), Burgers, K. (K.), Schippers, J., Weijenberg-Maes, B. (B.), Loo, I. (Inge) van, Havenith, T., Mulder, J.W. (J. W.), Vrouenraets, B.C. (Bart), Lauw, F.N. (F. N.), van Broekhuizen, M. (Marjolein), Vlasblom, D.J., Smits, P.H.M. (Paul), Weijer, S. (S.), El Moussaoui, R., Bosma, A.S. (A. S.), Vonderen, M.G.A. van, Van Houte, D.P.F., Kampschreur, L.M., Dijkstra, K. (K.), Faber, S., Weel, J. (J.), Kootstra, J.G. (Jille), Delsing, C.E. (C. E.), Van Der Burg-Van De Plas, M. (M.), Heins, H., Lucas, E. (E.), Kortmann, B., Van Twillert, G. (G.), Renckens, R. (Rosemarijn), Ruiter-Pronk, D. (D.), Van Truijen-Oud, F.A., Cohen Stuart, J.W.T. (James), IJzerman, E.P.F. (Ed), Jansen, R.J. (Roel), Rozemeijer, W. (Wouter), Van Der Reijden, W.A. (W. A.), Berk, G.E.L. (Guido) van den, Blok, W.L. (Willem), Frissen, P.H.J., Lettinga, K.D. (Kamilla), Schouten, W.E.M.I. (Ineke), Veenstra, J. (Jan), Brouwer, C.J., Geerders, G.F., Hoeksema, K., Kleene, M.J., Van Der Meché, I.B., Spelbrink, M. (M.), Toonen, A.J.M., Wijnands, S. (S.), Kwa, S.L.S. (Stefan), Regez, R.M. (Rosa), Crevel, R. (Reinout) van, Keuter, M. (Monique), Ven, A.D. (Andre´) van, Ter Hofstede, H.J.M. (H. J.M.), Dofferhoff, A.S.M. (Anton), Hoogerwerf, J. (J.), Grintjes-Huisman, K.J.T., De Haan, M. (M.), Marneef, M. (M.), Hairwassers, A. (A.), Rahamat-Langendoen, J. (J.), Stelma, F.F. (Foekje), Burger, D.M. (David), Gisolf, E.H. (Elisabeth), Hassing, R.J. (Robert), Claassen, M.A.A. (Mark), Ter Beest, G. (G.), Van Bentum, P.H.M., Langebeek, N. (Nienke), Tiemessen, R. (R.), Swanink, C. (Caroline), Lelyveld, S.F.L. van, Soetekouw, R. (Robert), Van Der Prijt, L.M.M., Van Der Swaluw, J. (J.), Bermon, N. (N.), Jansen, R. (R.), Herpers, B.L. (B. L.), Veenendaal, D. (Dick), Verhagen, D.W.M. (Dominique), Van Wijk, M. (M.), Bierman, W.F.W. (Wouter), Bakker, M. (M.), Kleinnijenhuis, J. (J.), Kloeze, E. (E.), Stienstra, Y. (Y.), Wilting, K.R., Wouthuyzen-Bakker, M. (Marjan), Boonstra, P.A. (André), Van Der Meulen, P.A., De Weerd, D.A., Niesters, H.G.M. (Bert), Van Leer-Buter, C. (Coretta), Knoester, M. (M.), Hoepelman, I.M. (Ilja Mohandas), Barth, R.E. (R. E.), Bruns, A.H.W. (A. H.W.), Ellerbroek, P.M. (P.), Mudrikova, T. (Tania Tania), Oosterheert, J.J. (Jan Jelrik), Schadd, E.M. (E. M.), Wassenberg, M.W.M., Van Zoelen, M.A.D. (M. A.D.), Aarsman, K. (K.), Van Elst-Laurijssen, D.H.M. (D. H.M.), De Kroon, I. (I.), Van Rooijen, C.S.A.M. (C. S.A.M.), Van Berkel, M. (M.), Schuurman, R. (Rob), Verduyn-Lunel, F., Wensing, A. (Amj), Peters, E.J.G., Van Agtmael, M.A. (M. A.), Bomers, M., Heitmuller, M. (M.), Laan, L.M., Ang, C.W. (Wim), Houdt, R. van, Pettersson, A. (Annika), Vandenbroucke-Grauls, C.M.J.E. (Christina), Bezemer, D.O. (Daniela), Sighem, A.I. (Ard) van, Smit, C. (Cees), Wit, F. (Ferdinand), Boender, T.S. (T. S.), Zaheri, S. (S.), Hillebregt, M.M.J. (Mariska), De Jong, A., Bergsma, D., Grivell, S., Jansen, A. (A.), Raethke, M., Meijering, R., Rutkens, T. (T.), De Groot, L. (L.), Van Den Akker, M. (M.), Bakker, Y., Bezemer, M. (M.), Claessen, E., El Berkaoui, A. (A.), Geerlinks, J. (J.), Koops, J. (J.), Kruijne, E., Lodewijk, C., Van Der Meer, R. (R.), Munjishvili, L., Paling, F. (F.), Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M. (Marianne), Timmerman, A. (A.), Tuijn, E., Veenenberg, L., Van Der Vliet, S. (S.), Wisse, A. (A.), De Witte, E.C. (E. C.), Woudstra, T., Tuk, B. (B.), Boerekamps, A. (Anne), Newsum, A.M. (Astrid M.), Smit, C. (Colette), Arends, J.E. (Joop), Richter, C. (Clemens), Reiss, P. (Peter), Rijnders, B.J.A. (Bart), Brinkman, K. (Kees), Valk, M. (Marc) van der, Geerlings, S.E. (Suzanne), Godfried, M.H., Goorhuis, A. (Abraham), Hovius, J.W.R. (Joppe), Meer, J.T.M. (J. T M) van der, Kuijpers, T.W. (Taco W.), Nellen, F.J.B. (F. J B), Van Der Poll, D.T. (D. T.), Prins, J.M. (Jan), Van Vugt, H.J.M. (H. J.M.), Wiersinga, W.J. (W. J.), Wit, F.W.N.M. (Ferdinand), Van Duinen, M. (M.), Van Eden, J., Van Hes, A.M.H., Mutschelknauss, M., Nobel, H.E., Pijnappel, F.J.J., Weijsenfeld, A.M., Jurriaans, S. (Suzanne), Back, N. (Nicole), Zaaijer, H.L. (Hans), Berkhout, B. (Ben), Cornelissen, M. (Marion), Schinkel, C.J., Wolthers, K.C. (Katja), Van Den Berge, M., Stegeman, A., Baas, S., Hage De Looff, L. (L.), Wintermans, B. (B.), Veenemans, J. (J.), Pronk, M.J.H. (Marjolijn), Ammerlaan, H.S.M. (Heidi), De Munnik, E.S., Jansz, A.R. (A. R.), Tjhie, J. (J.), Wegdam, M.C.A., Deiman, B. (B.), Scharnhorst, V., Eeden, A. (Arne) van, Brokking, W. (W.), Groot, M.M. (Marieke), Elsenburg, L.J.M. (L. J.M.), Damen, M. (M.), Kwa, I.S., Kasteren, M.E.E. (Marjo) van, Brouwer, A.E., Van Erve, R. (R.), De Kruijf-Van De Wiel, B.A.F.M. (B. A.F.M.), Keelan-Pfaf, S. (S.), Van Der Ven, B. (B.), Van Der Ven, B., Buiting, A.G.M. (Anton), Kabel, P.J. (P. J.), Versteeg, D., Ende, M.E. (Marchina) van der, Bax, H.I. (Hannelore), Gorp, E.C.M. (Eric) van, Nouwen, J.L. (Jan), Schurink, C.A.M. (Carolina), Verbon, A. (Annelies), Vriessluijs, T.E.M.S. (Theodora) de, De Jong-Peltenburg, N.C. (N. C.), Bassant, N., Van Beek, J.E.A., Vriesde, M., van Zonneveld, L. (Laura), Van Den Berg-Cameron, H.J., Groot, J.C. (Jan Cees) de, De Zeeuw-De Man, M., Boucher, C.A.B. (Charles), Koopmans D.V.M., M.P.G. (Marion), Kampen, J.J.A. (Jeroen) van, Pas, S.D. (Suzan), Branger, J., Rijkeboer-Mes, A. (A.), Duijf-Van De Ven, C.J.H.M., Schippers, E.F. (E. F.), Nieuwkoop, C. (Cees) van, Van IJperen, J.M. (J. M.), Geilings, J. (J.), Van Der Hut, G., Burgel, N.D. (Nathalie ) van, Leyten, E.M.S. (Eliane), Gelinck, L.B.S. (Luc), Van Hartingsveld, A.Y. (A. Y.), Meerkerk, C., Wildenbeest, G.S., Heikens, E. (E.), Groeneveld, P.H.P. (P. H.P.), Bouwhuis, J.W. (Jolande), Lammers, A.J.J. (A. J.J.), Kraan, S. (S.), Van Hulzen, A.G.W., Van Der Bliek, G.L. (G. L.), Bor, P.C.J., Bloembergen, P. (Peter), Wolfhagen, M.J.H.M., Ruijs, G. (G.), Kroon, F.P. (F. P.), Boer, M.G.J. (Mark) de, Scheper, H. (H.), Jolink, A. (Albert), Vollaard, A. (Albert), Dorama, W. (Willemien), Van Holten, N. (N.), Claas, E.C.J. (Eric), Wessels, E. (E.), Hollander, J.G. (Jan) den, Pogány, K. (Katalin), Roukens, A. (A.), Kastelijns, M. (M.), Smit, J.V., Smit, E., Struik-Kalkman, D. (D.), Tearno, C. (C.), Van Niekerk, T., Pontesilli, O. (Oscar), Lowe, S.H. (S. H.), Oude Lashof, A. (A.), Posthouwer, D. (Dirk), Ackens, R.P. (R. P.), Burgers, K. (K.), Schippers, J., Weijenberg-Maes, B. (B.), Loo, I. (Inge) van, Havenith, T., Mulder, J.W. (J. W.), Vrouenraets, B.C. (Bart), Lauw, F.N. (F. N.), van Broekhuizen, M. (Marjolein), Vlasblom, D.J., Smits, P.H.M. (Paul), Weijer, S. (S.), El Moussaoui, R., Bosma, A.S. (A. S.), Vonderen, M.G.A. van, Van Houte, D.P.F., Kampschreur, L.M., Dijkstra, K. (K.), Faber, S., Weel, J. (J.), Kootstra, J.G. (Jille), Delsing, C.E. (C. E.), Van Der Burg-Van De Plas, M. (M.), Heins, H., Lucas, E. (E.), Kortmann, B., Van Twillert, G. (G.), Renckens, R. (Rosemarijn), Ruiter-Pronk, D. (D.), Van Truijen-Oud, F.A., Cohen Stuart, J.W.T. (James), IJzerman, E.P.F. (Ed), Jansen, R.J. (Roel), Rozemeijer, W. (Wouter), Van Der Reijden, W.A. (W. A.), Berk, G.E.L. (Guido) van den, Blok, W.L. (Willem), Frissen, P.H.J., Lettinga, K.D. (Kamilla), Schouten, W.E.M.I. (Ineke), Veenstra, J. (Jan), Brouwer, C.J., Geerders, G.F., Hoeksema, K., Kleene, M.J., Van Der Meché, I.B., Spelbrink, M. (M.), Toonen, A.J.M., Wijnands, S. (S.), Kwa, S.L.S. (Stefan), Regez, R.M. (Rosa), Crevel, R. (Reinout) van, Keuter, M. (Monique), Ven, A.D. (Andre´) van, Ter Hofstede, H.J.M. (H. J.M.), Dofferhoff, A.S.M. (Anton), Hoogerwerf, J. (J.), Grintjes-Huisman, K.J.T., De Haan, M. (M.), Marneef, M. (M.), Hairwassers, A. (A.), Rahamat-Langendoen, J. (J.), Stelma, F.F. (Foekje), Burger, D.M. (David), Gisolf, E.H. (Elisabeth), Hassing, R.J. (Robert), Claassen, M.A.A. (Mark), Ter Beest, G. (G.), Van Bentum, P.H.M., Langebeek, N. (Nienke), Tiemessen, R. (R.), Swanink, C. (Caroline), Lelyveld, S.F.L. van, Soetekouw, R. (Robert), Van Der Prijt, L.M.M., Van Der Swaluw, J. (J.), Bermon, N. (N.), Jansen, R. (R.), Herpers, B.L. (B. L.), Veenendaal, D. (Dick), Verhagen, D.W.M. (Dominique), Van Wijk, M. (M.), Bierman, W.F.W. (Wouter), Bakker, M. (M.), Kleinnijenhuis, J. (J.), Kloeze, E. (E.), Stienstra, Y. (Y.), Wilting, K.R., Wouthuyzen-Bakker, M. (Marjan), Boonstra, P.A. (André), Van Der Meulen, P.A., De Weerd, D.A., Niesters, H.G.M. (Bert), Van Leer-Buter, C. (Coretta), Knoester, M. (M.), Hoepelman, I.M. (Ilja Mohandas), Barth, R.E. (R. E.), Bruns, A.H.W. (A. H.W.), Ellerbroek, P.M. (P.), Mudrikova, T. (Tania Tania), Oosterheert, J.J. (Jan Jelrik), Schadd, E.M. (E. M.), Wassenberg, M.W.M., Van Zoelen, M.A.D. (M. A.D.), Aarsman, K. (K.), Van Elst-Laurijssen, D.H.M. (D. H.M.), De Kroon, I. (I.), Van Rooijen, C.S.A.M. (C. S.A.M.), Van Berkel, M. (M.), Schuurman, R. (Rob), Verduyn-Lunel, F., Wensing, A. (Amj), Peters, E.J.G., Van Agtmael, M.A. (M. A.), Bomers, M., Heitmuller, M. (M.), Laan, L.M., Ang, C.W. (Wim), Houdt, R. van, Pettersson, A. (Annika), Vandenbroucke-Grauls, C.M.J.E. (Christina), Bezemer, D.O. (Daniela), Sighem, A.I. (Ard) van, Smit, C. (Cees), Wit, F. (Ferdinand), Boender, T.S. (T. S.), Zaheri, S. (S.), Hillebregt, M.M.J. (Mariska), De Jong, A., Bergsma, D., Grivell, S., Jansen, A. (A.), Raethke, M., Meijering, R., Rutkens, T. (T.), De Groot, L. (L.), Van Den Akker, M. (M.), Bakker, Y., Bezemer, M. (M.), Claessen, E., El Berkaoui, A. (A.), Geerlinks, J. (J.), Koops, J. (J.), Kruijne, E., Lodewijk, C., Van Der Meer, R. (R.), Munjishvili, L., Paling, F. (F.), Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M. (Marianne), Timmerman, A. (A.), Tuijn, E., Veenenberg, L., Van Der Vliet, S. (S.), Wisse, A. (A.), De Witte, E.C. (E. C.), Woudstra, T., and Tuk, B. (B.)

Abstract

Background The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa–based regimen had failed in 54. Conclusions Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.

Published
2018
Full Text
View/download PDF

21. X-chromosome Forkhead Box P3 polymorphisms associate with atopy in girls in three Dutch birth cohorts

Author

Bottema, R.W., Kerkhof, M. van de, Reijmerink, N.E., Koppelman, G.H., Thijs, C., Stelma, F.F., Smit, H.A., Brunekreef, B., Schayck, C.P. van, Postma, D.S., Groningen Research Institute for Asthma and COPD (GRIAC), Epidemiologie, Medische Microbiologie, Family Medicine, RS: CAPHRI School for Public Health and Primary Care, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
X-chromosome, DYSREGULATION, HAPLOTYPE MAP, FOXP3, atopy, CHILDHOOD, Pathogenesis and modulation of inflammation [N4i 1], ALLERGIC DISEASE, FOOD, gender, ASTHMA, genetics, REGULATORY T-CELLS, TRANSCRIPTION FACTOR, IGE, Infection and autoimmunity [NCMLS 1]
Abstract

To cite this article: Bottema RWB, Kerkhof M, Reijmerink NE, Koppelman GH, Thijs C, Stelma FF, Smit HA, Brunekreef B, van Schayck CP, Postma DS. X-chromosome Forkhead Box P3 polymorphisms associate with atopy in girls in three Dutch birth cohorts. Allergy 2009; DOI: 10.1111/j.1398-9995.2009.02291.x. Abstract Background: The Forkhead Box P3 (FOXP3) gene, located on the X-chromosome, encodes a transcription factor that directs T cells toward a regulatory phenotype. Regulatory T cells may suppress development of atopy. We evaluated whether single-nucleotide polymorphisms (SNPs) of FOXP3 are associated with atopy development in childhood. Methods: Seven SNPs in FOXP3 were genotyped in 3062 children (51% boys) participating in the Allergenic study, which consists of three Dutch birth cohorts (PIAMA, PREVASC and KOALA). Association of FOXP3 SNPs with total serum IgE and sensitisation (presence of specific serum IgE to egg, milk, and indoor, i.e. house-dust mite, cat, and/or dog allergens) was investigated at ages 1, 2, 4, and 8. Analysis of variance and logistic regression were performed, stratified for gender. Results: Our most consistent finding was observed for sensitisation to egg and indoor allergens. In girls, five FOXP3 SNPs (rs5906761, rs2294021, rs2294019, rs6609857 and rs3761548) were significantly associated with sensitisation to egg at ages 1 and 2 and with sensitisation to indoor allergens at age 2 (P < 0.05), but not at 4 and 8, a finding that was observed across the three cohorts. Rs5906761 and rs2294021 were associated with remission of sensitisation to food allergens in boys, as tested in the PIAMA cohort. Conclusion: This is the first study showing across three cohorts that X-chromosomal FOXP3 genotypes may contribute to development of sensitisation against egg and indoor allergens in girls in early childhood. In addition, an association with remission of sensitisation to food allergens existed in boys only.

Published
2010

22. Adenovirus Infection in Immunocompetent Children: Not Always as Innocent as Assumed

Author

Corcoran, Moniek, van Loo, Inge, Stelma, F.F., van Well, Gijs, MUMC+: MA Arts Assistenten Kindergeneeskunde (9), MUMC+: DA MMI Infectieserologie (9), MUMC+: DA MMI AIOS (9), Medische Microbiologie, MUMC+: DA MMI Staf (9), RS: NUTRIM - R1 - Metabolic Syndrome, MUMC+: MA Medische Staf Kindergeneeskunde (9), and Kindergeneeskunde

Published
2016

23. Diminished Impact of Ethnicity as a Risk Factor for Chronic Kidney Disease in the Current HIV Treatment Era

Author

Schoffelen, A.F., Smit, C., Lelyveld, S.F. van, Vogt, L., Bauer, M.P., Reiss, P., Hoepelman, A.I., Barth, R.E., Burger, D.M., Koopmans †, P.P., Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Crevel, R. van, Albers, M.A., Bosch, M.E.W., Grintjes-Huisman, K.J.T., Zomer, B.J., Stelma, F.F., Med Microbiol, Infect Dis & Infect Prev, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R4 - Health Inequities and Societal Participation, Interne Geneeskunde, Amsterdam Cardiovascular Sciences, Amsterdam Public Health, Nephrology, Amsterdam institute for Infection and Immunity, Global Health, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Center of Experimental and Molecular Medicine, Graduate School, Medical Microbiology and Infection Prevention, Other departments, Gastroenterology and Hepatology, and Surgery

Subjects
Male, Pathology, estimated glomerular filtration rate, Cross-sectional study, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], HIV Infections, urologic and male genital diseases, Interquartile range, Risk Factors, Prevalence, Immunology and Allergy, Renal Insufficiency, Chronic, Non-U.S. Gov't, Netherlands, Medicine(all), Research Support, Non-U.S. Gov't, Hazard ratio, Middle Aged, female genital diseases and pregnancy complications, Infectious Diseases, Cohort, ethnicity, Female, Adult, medicine.medical_specialty, Anti-HIV Agents, Organophosphonates, Observational Study, Research Support, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Journal Article, Humans, Risk factor, Renal Insufficiency, Chronic, Tenofovir, Africa South of the Sahara, business.industry, Adenine, renal function, HIV, Odds ratio, medicine.disease, Comorbidity, sub-Saharan African origin, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Cross-Sectional Studies, business, genetic predisposition, chronic kidney disease, Kidney disease
Abstract

Contains fulltext : 155028.pdf (Publisher’s version ) (Closed access) BACKGROUND: Chronic kidney disease (CKD) is an important comorbidity during human immunodeficiency virus (HIV) infection. Historically, HIV-associated nephropathy has been the predominant cause of CKD and has primarily been observed in people of African ancestry. This study aims to investigate the role of ethnicity in relation to CKD risk in recent years. METHODS: Analyses were performed including 16 836 patients from the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. Baseline was defined as the first available creatinine level measurement after 1 January 2007; CKD was defined as a glomerular filtration rate of

Published
2015

24. Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions

Author

Mothapo, K.M., Oever, J. ten, Koopmans, P.P., Stelma, F.F., Burm, S., Bajramovic, J., Verbeek, M.M., Olde Rikkert, M.G.M., Netea, M.G., Koopman, G., Ven, A.J.A.M. van der, Mothapo, K.M., Oever, J. ten, Koopmans, P.P., Stelma, F.F., Burm, S., Bajramovic, J., Verbeek, M.M., Olde Rikkert, M.G.M., Netea, M.G., Koopman, G., and Ven, A.J.A.M. van der

Abstract

Contains fulltext : 169827.pdf (publisher's version ) (Closed access), HIV in the central nervous system (CNS) mainly infects microglial cells which are known to express toll-like receptors (TLRs). This paper aimed to study the role of soluble TLR2 (sTLR2), sTLR4, and other inflammatory markers in cerebrospinal fluid (CSF) in HIV/Simian immunodeficiency virus (SIV)-related neurological sequelae. We determined sTLR2 and sTLR4 levels in CSF and serum/plasma of SIV-infected rhesus macaques with and without neurological sequelae, as well as in HIV-infected patients with and without cognitive impairments and Alzheimer's disease (AD) patients and matched controls. CSF cytokines and chemokines levels were analyzed in macaques as markers of neuroinflammation, while neopterin and S100B CSF concentrations were measured in HIV-infected patients as microglial and astrocyte marker, respectively. We found detectable levels of sTLR2 and sTLR4 in CSF of macaques and humans. Furthermore, CSF sTLR2 and sTLR4 concentrations were higher in SIV-infected macaques with neurological sequelae compared to those without neurological complications (p = 0.0003 and p = 0.0006, respectively). CSF IL-8 and monocyte chemoattractant protein-1 (MCP-1) levels were elevated in macaques with neurological sequelae, and a positive correlation was found between CSF levels of sTLR2/4 and IL-8 and MCP-1. Also in humans, elevated CSF sTLR4 levels were found in HIV-infected patients with cognitive impairments compared to HIV-infected patients with normal cognition (p = 0.019). Unlike CSF S100B levels, neopterin correlated positively with sTLR2 and sTLR4. No difference was found in plasma and CSF sTLR2 and sTLR4 levels between AD patients and control subjects (p = 0.26). In conclusion, CSF sTLR2 and sTLR4 may play a role in HIV/SIV-related neuroinflammation and subsequent neuropathology.

Published
2017

25. Bacterial Tracheitis and Septic Shock

Author

Tak, R.O., Semmekrot, B.A., Warris, A., Yntema, J.L., Stelma, F.F., Neeleman, C., Tak, R.O., Semmekrot, B.A., Warris, A., Yntema, J.L., Stelma, F.F., and Neeleman, C.

Abstract

Item does not contain fulltext

Published
2016

26. Inflammation in HIV-associated neurocognitive disorders

Author

Ven, A.J.A.M. van der, Mphahlele, J., Stelma, F.F., Koopmans †, P.P., Mothapo, K.M., Ven, A.J.A.M. van der, Mphahlele, J., Stelma, F.F., Koopmans †, P.P., and Mothapo, K.M.

Abstract

RU Radboud Universiteit, 6 juni 2016, Promotores : Ven, A.J.A.M. van der, Mphahlele, J. Co-promotores : Stelma, F.F., Koopmans †, P.P., Item does not contain fulltext

Published
2016

27. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis.

Author

Leeflang, M.M., Ang, C.W., Berkhout, J., Bijlmer, H.A., Bortel, W. Van, Brandenburg, A.H., Burgel, N.D. Van, Dam, A.P. Van, Dessau, R.B., Fingerle, V., Hovius, J.W., Jaulhac, B., Meijer, B., Pelt, W. Van, Schellekens, J.F., Spijker, R., Stelma, F.F., Stanek, G., Verduyn-Lunel, F., Zeller, H., Sprong, H., Leeflang, M.M., Ang, C.W., Berkhout, J., Bijlmer, H.A., Bortel, W. Van, Brandenburg, A.H., Burgel, N.D. Van, Dam, A.P. Van, Dessau, R.B., Fingerle, V., Hovius, J.W., Jaulhac, B., Meijer, B., Pelt, W. Van, Schellekens, J.F., Spijker, R., Stelma, F.F., Stanek, G., Verduyn-Lunel, F., Zeller, H., and Sprong, H.

Abstract

Contains fulltext : 171709.pdf (publisher's version ) (Open Access)

Published
2016

29. Absolute lymphocyte count predicts the response to new H1N1 vaccination in pediatric cancer patients

Author

Mavinkurve-Groothuis, A.M.C., Flier, M. van der, Stelma, F.F., Leer-Buter, C.C. van, Preijers, F.W.M.B., and Hoogerbrugge, P.M.

Subjects
Pathogenesis and modulation of inflammation [N4i 1], Age-related aspects of cancer [ONCOL 2], Translational research [ONCOL 3], Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1], Age-related aspects of cancer Immune Regulation [ONCOL 2]
Abstract

Item does not contain fulltext We measured the vaccination response to the new H1N1 in relation to lymphocyte count prior to vaccination in pediatric cancer patients. Absolute lymphocyte count above the lower normal limits (LNL) for age prior to vaccination predicts the response to influenza vaccination in pediatric cancer patients treated with chemotherapy.

Published
2013

30. Circulating galectin-3 in infections and non-infectious inflammatory diseases

Author

Ten Oever, J. Giamarellos-Bourboulis, E.J. Van De Veerdonk, F.L. Stelma, F.F. Simon, A. Janssen, M. Johnson, M. Pachot, A. Kullberg, B.-J. Joosten, L.A.B. Netea, M.G.

Abstract

Recent studies point to a dual role for galectin-3 as both a circulating damage-associated molecular pattern and a cell membrane-associated pattern recognition receptor. The aim of this study was to assess the potential of circulating galectin-3 for discriminating between infections and non-infectious inflammatory disorders on the one hand, and between fungal and bacterial infections on the other. Galectin-3 and C-reactive protein (CRP) were measured in the plasma of 127 patients with either non-infectious inflammatory disorders (gout, autoinflammatory syndrome or pancreatitis) or an infection (viral lower respiratory tract infection, bacterial sepsis or candidaemia). Circulating galectin-3 concentrations were increased in patients with infections when compared with healthy volunteers or patients with non-infectious inflammatory diseases. At cut-off values with a specificity of 95 %, the sensitivity of galectin-3 (>20.6 ng/ml) to discriminate between an infection and non-infectious inflammation was higher than that of CRP (>156 mg/l): 43 % [95 % confidence interval (CI) 33-53 %] versus 27 % (95 % CI 19-37 %), p = 0.03. After exclusion of patients with CRP 20.6 ng/ml could identify 41 % (95 % CI 29-53 %) of the patients with an infection at the cost of one false-positive with non-infectious inflammation. Using this sequential approach, 57 % of the patients with an infection could be selected. Galectin-3 concentrations were similar in patients with bacterial and Candida sepsis, while being lower in viral respiratory infections. Although galectin-3 does not discriminate between bacterial and Candida sepsis, the sequential use of CRP and galectin-3 in distinguishing infectious diseases from non-infectious inflammation may be superior to CRP alone. © 2013 Springer-Verlag Berlin Heidelberg.

Published
2013

31. [Borrelial lymphocytoma]

Author

Schatorje, E.J.H., Steeg, H.J. van der, Stelma, F.F., Hebeda, K.M., and Warris, A.

Subjects
Invasive mycoses and compromised host [N4i 2], Health aging / healthy living [IGMD 5], Evaluation of complex medical interventions [NCEBP 2], Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1], Translational research Tissue engineering and pathology [ONCOL 3]
Abstract

Item does not contain fulltext BACKGROUND: Borrelial lymphocytoma is a relatively rare but typical presentation of Lyme disease. Predilection sites are the ears in children and chest/nipples in adults. It is treated like an erythema migrans and has a good prognosis. CASE DESCRIPTION: A 16-year-old boy presented with a swollen, red and painful right nipple since several months. An ultrasound showed normal breast tissue. The patient was referred to the pediatric surgeon who performed an incision biopsy. Histopathological examination revealed follicular hyperplasia without signs of malignancy. An infectious cause, most likely Lyme disease, was suspected. Serological analysis and PCR of the tissue confirmed the diagnosis of a borrelial lymphocytoma, and the patient was treated with doxycycline with good result. CONCLUSION: Early recognition of the characteristic clinical presentation of borrelial lymphocytoma, supported by positive results from serologic testing for Lyme disease, avoids the need for additional and invasive diagnostic tests.

Published
2013

34. Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.

Author

Prinsen, H., Laarhoven, H.W. van, Pots, J.M., Duiveman, T., Mulder, S.F., Herpen, C.M.L. van, Jacobs, J.F.M., Leer, J.W.H., Bleijenberg, G., Stelma, F.F., Torensma, R., Vries, I.J.M. de, Prinsen, H., Laarhoven, H.W. van, Pots, J.M., Duiveman, T., Mulder, S.F., Herpen, C.M.L. van, Jacobs, J.F.M., Leer, J.W.H., Bleijenberg, G., Stelma, F.F., Torensma, R., and Vries, I.J.M. de

Abstract

Contains fulltext : 153018.pdf (Publisher’s version ) (Open Access)

Published
2015

35. Has CXCL13 an added value in diagnosis of neurosyphilis?

Author

Mothapo, K.M., Verbeek, M.M., Velden, L.B. van der, Ang, C.W., Koopmans †, P.P., Ven, A. van der, Stelma, F.F., Mothapo, K.M., Verbeek, M.M., Velden, L.B. van der, Ang, C.W., Koopmans †, P.P., Ven, A. van der, and Stelma, F.F.

Abstract

Contains fulltext : 155396.pdf (publisher's version ) (Open Access), In patients with syphilis, central nervous system (CNS) involvement is often difficult to determine. In patients who also are infected with human immunodeficiency virus (HIV), this is even more challenging, as cerebrospinal fluid (CSF) pleocytosis can be attributed to HIV, syphilis, or both. Hence, this study investigated (i) CSF chemokine (C-X-C motif) ligand 13 (CXCL13) as a potential marker to diagnose neurosyphilis in HIV-infected individuals and (ii) the added value of CSF CXCL13 to conventional CSF biomarkers, such as the rapid plasma reagin test (RPR), in diagnosing neurosyphilis. We included 103 syphilis patients from two centers in The Netherlands: 47 non-HIV-infected patients and 56 HIV-infected patients. A positive CSF-RPR was regarded as the gold standard for neurosyphilis. CSF CXCL13 levels were significantly higher in neurosyphilis patients when neurosyphilis was diagnosed by CSF-RPR (P = 0.0002) than in the syphilis control group. The sensitivity and specificity of CSF CXCL13 (cutoff of 76.3 pg/ml) to diagnose neurosyphilis by using positive CSF-RPR as the gold standard were 50% and 90%, respectively. CSF CXCL13 had an added value to CSF-RPR positivity in 70% of HIV-positive patients and in 33% of HIV-negative patients. Our data show that CSF CXCL13 might be a potential additional marker in neurosyphilis when other markers are not conclusive. The added value of CSF CXCL13 measurement to the current neurosyphilis gold standard appears to benefit HIV-positive patients more than HIV-negative patients.

Published
2015

37. X-chromosome Forkhead Box P3 polymorphisms associate with atopy in girls in three Dutch birth cohorts

Author

Bottema, R.W.B., Kerkhof, M., Reijmerink, N.E., Koppelman, G.H., Thijs, C., Stelma, F.F., Smit, H.A., Brunekreef, B., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep IRAS

Abstract

BACKGROUND: The Forkhead Box P3 (FOXP3) gene, located on the X-chromosome, encodes a transcription factor that directs T cells toward a regulatory phenotype. Regulatory T cells may suppress development of atopy. We evaluated whether single-nucleotide polymorphisms (SNPs) of FOXP3 are associated with atopy development in childhood. METHODS: Seven SNPs in FOXP3 were genotyped in 3062 children (51% boys) participating in the Allergenic study, which consists of three Dutch birth cohorts (PIAMA, PREVASC and KOALA). Association of FOXP3 SNPs with total serum IgE and sensitisation (presence of specific serum IgE to egg, milk, and indoor, i.e. house-dust mite, cat, and/or dog allergens) was investigated at ages 1, 2, 4, and 8. Analysis of variance and logistic regression were performed, stratified for gender. RESULTS: Our most consistent finding was observed for sensitisation to egg and indoor allergens. In girls, five FOXP3 SNPs (rs5906761, rs2294021, rs2294019, rs6609857 and rs3761548) were significantly associated with sensitisation to egg at ages 1 and 2 and with sensitisation to indoor allergens at age 2 (P

Published
2010

38. CD14 polymorphisms in mother and infant, soluble CD14 in breast milk and atopy development in the infant (KOALA Study)

Author

Snijders, B.E., Stelma, F.F., Reijmerink, N.E., Thijs, C., Steege, G. van der, Damoiseaux, J.G., Brandt, P.A. van den, Ree, R. van, Postma, D.S., Koppelman, G.H., Epidemiologie, Medische Microbiologie, Interne Geneeskunde, RS: CAPHRI School for Public Health and Primary Care, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
ENVIRONMENT, atopic dermatitis, PLASMA, PARTY DIAGNOSTIC-CRITERIA, CHILDREN, gene-environment interactions, GENE, PROMOTER POLYMORPHISM, immunoglobulin E, Pathogenesis and modulation of inflammation [N4i 1], DERMATITIS, ANTIBODIES, eczema, IGE, CD14, Infection and autoimmunity [NCMLS 1], IMMUNOGLOBULIN-E
Abstract

Item does not contain fulltext Different CD14 polymorphisms have been associated with atopic phenotypes in infants. In addition, CD14 genotypes of breastfeeding mothers have been associated with soluble CD14 (sCD14) levels in breast milk. The role of CD14 genotypes of infant and mother and their interaction with sCD14 levels in breast milk in atopy development remain to be established. We aimed to study the associations of CD14 single nucleotide polymorphisms (SNPs), and their interaction with breast milk sCD14, with atopy development until age two. In addition, we assessed whether levels of sCD14 in breast milk associated with SNPs in CD14. Four SNPs in CD14 gene were investigated in 698 infants and 188 mothers. Associations between these SNPs, sCD14 and atopy development were analyzed in multiple logistic or linear regression models. The CD14/-1619 SNP was associated with eczema. CC homozygotes showed a lower risk of eczema vs. TT homozygotes (adjusted odds ratio = 0.56, 95% confidence interval 0.33-0.96) in a co-dominant model. Breast milk sCD14 levels did not significantly modify the effect of the child's CD14 genotype on atopy development (p interaction > or =0.10). Maternal CD14 SNPs were not significantly associated with sCD14 levels in breast milk (anova, p > or = 0.48). We found only an association between CC homozygozity of SNP CD14/-1619 and eczema. Our data did not support a modifying role of breast milk sCD14 levels on the relationship between CD14 genotype and atopy development until age 2 yr. 01 mei 2010

Published
2010

39. Timing of infection and development of wheeze, eczema, and atopic sensitization during the first 2 yr of life: The KOALA Birth Cohort Study

Author

Mommers, M., Thijs, C., Stelma, F.F., Penders, J., Reimerink, J., Ree, R. van, Koopmans, M., Other departments, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Experimental Immunology, Epidemiologie, Med Microbiol, Infect Dis & Infect Prev, RS: CAPHRI School for Public Health and Primary Care, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
Pathogenesis and modulation of inflammation [N4i 1], Infection and autoimmunity [NCMLS 1]
Abstract

Item does not contain fulltext To investigate if infections in pregnancy and very early in life present a risk for wheezing, eczema, or atopic sensitization in later infancy. A total of 2319 children enrolled before birth in the KOALA Birth Cohort Study were followed during their first 2 yr of life using repeated questionnaires. Information was obtained on common colds, fever, and diarrhea with fever as well as on wheeze and eczema at ages 3 and 7 months and 1 and 2 yr, respectively. Blood samples were collected from 786 children at age 2 yr for specific immunoglobulin E analyses. Children with a common cold [adjusted odds ratio (aOR) 2.03 95% CI 1.21-3.41] or fever episode (aOR 1.81 95% CI 1.10-2.96) in the first 3 months of life had a higher risk of new onset wheeze in the second year of life compared to children who had not. For children with diarrhea with fever in the first 3 months of life, the aOR for new onset wheeze in the second year of life was 3.94 (95% CI 1.36-11.40) compared to children without diarrhea. Infections becoming clinically manifest during the first 3 months of life may be a general marker for a wheezy phenotype. 01 september 2010

Published
2010

40. Interaction of T-cell and antigen presenting cell co-stimulatory genes in childhood IgE

Author

Bottema, R.W.B., Postma, D.S., Reijmerink, N.E., Thijs, C., Stelma, F.F., Smit, H.A., van Schayck, C.P., Brunekreef, B., Koppelman, G.H., Kerkhof, M., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Groningen Research Institute for Asthma and COPD (GRIAC), Epidemiologie, Medische Microbiologie, Family Medicine, RS: NUTRIM - R2 - Gut-liver homeostasis, and RS: CAPHRI School for Public Health and Primary Care

Subjects
Pulmonary and Respiratory Medicine, Male, T-Lymphocytes, BTLA, multifactor dimensionality reduction, Antigen-Presenting Cells, Cell Communication, SUSCEPTIBILITY, Immunoglobulin E, Atopy, MULTIFACTOR-DIMENSIONALITY REDUCTION, Co-stimulation, Antigen, genetic interaction, Medicine, Humans, Prospective Studies, Child, POLYMORPHISMS, KOREAN CHILDREN, CD40, biology, BIRTH COHORT, business.industry, Haplotype, co-stimulation, Infant, ASSOCIATION, medicine.disease, PREVENTION, SENSITIZATION, Pathogenesis and modulation of inflammation [N4i 1], Gene Expression Regulation, ATOPY, Child, Preschool, Immunology, biology.protein, ASTHMA, Female, Antibody, business, Infection and autoimmunity [NCMLS 1]
Abstract

Item does not contain fulltext It is likely that multiple genes contribute to immunoglobulin (Ig)E production. Co-stimulatory molecules are crucial for the cross-talk between antigen presenting cells and T-lymphocytes which drives the IgE response. We evaluated gene-gene interactions of haplotype tagging polymorphisms in a pathway of 24 co-stimulatory genes in relation to serum IgE levels. We assessed this at ages 1-2 yrs and 6-8 yrs in 3,062 Dutch children from a pooled data set of three birth cohorts: PIAMA (Prevention and Incidence Asthma and Mite Allergy), PREVASC (Prevention of Asthma in Children) and KOALA (Child, parents and health: lifestyle and genetic constitution). Single- and multi-locus associations with serum IgE levels (3rd versus 1st tertile) were evaluated by Chi-squared tests and the multifactor dimensionality reduction (MDR) method in the following co-stimulatory genes: VTCN1, TNFRSF4, TNFRSF18, TNFRSF14, TNFSF18, TNFSF4, CD28, CTLA4, ICOS, PDCD1, BTLA, CD80, CD86, HLA-G, CD274, PDCD1LG2, CD276, LILRA4, LILRB1, LILRB2, LILRB4, CD40, ICOSLG, and CD40LG. We found multiple statistically significant single-locus ((S)) and multi-locus ((M)) associations for the genes VTCN1(SM), TNFSF18(SM), TNFSF4(S), CD28(S), CTLA4(M), ICOS(S), BTLA(M), CD80(M), CD86(SM), CD274(SM), PDCD1LG2(M), LILRA4(SM), LILRB4(M), and CD40(SM) with serum IgE. Two-locus interactions of CD86 with VTCN1 and CD274 with LILRA4 were confirmed by logistic regression. In conclusion, serum IgE levels are regulated by multiple gene-gene interaction effects in the co-stimulatory pathway. We suggest using research strategies that model multiple gene-gene interactions in genetic studies. 01 januari 2010

Published
2010

44. CD14/Toll-like receptors interact with bacteria and regulatory T-cells in the development of childhood asthma

Author

Klaassen, E.M., Kant, K.D. van de, Soeteman, M., Damoiseaux, J., Eys, G. van, Stobberingh, E.E., Stelma, F.F., Quaak, M., Schayck, C.P. van, Jobsis, Q., Dompeling, E., Klaassen, E.M., Kant, K.D. van de, Soeteman, M., Damoiseaux, J., Eys, G. van, Stobberingh, E.E., Stelma, F.F., Quaak, M., Schayck, C.P. van, Jobsis, Q., and Dompeling, E.

Abstract

Item does not contain fulltext

Published
2014

45. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab.

Author

Velden, W.J.F.M. van der, Mori, T., Stevens, W.B.C., Haan, A.F.J. de, Stelma, F.F., Blijlevens, N.M.A., Donnelly, J.P., Velden, W.J.F.M. van der, Mori, T., Stevens, W.B.C., Haan, A.F.J. de, Stelma, F.F., Blijlevens, N.M.A., and Donnelly, J.P.

Abstract

Item does not contain fulltext, The mortality associated with post-transplant lymphoproliferative disorder (PTLD) induced by EBV infection can be reduced by monitoring EBV by polymerase-chain-reaction and rituximab given pre-emptively. We performed a retrospective analysis of the risk factors for the occurrence of EBV infection/disease and EBV-related mortality among 273 consecutive recipients of a T-cell-depleted allo-SCT during two periods: (a) before the implementation of a comprehensive protocol (2006-2008) and (b) afterwards (2009-2011). EBV infection was detected in 61 (22%) cases, and 28 cases were considered to have had EBV disease. Treatment with antithymocyte globulin was the most important risk factor (odds ratio (OR) 2.4; 95% confidence interval (CI) 1.3-4.2, P=0.001). After implementation of the protocol, in patients experiencing EBV infection, pre-emptive therapy was started more often and sooner (median 3 vs 6 days, P=0.002). Moreover, there were fewer cases of monomorphic PTLD (4/33 (12%) vs 11/28 (39%), P=0.01), and the EBV-related mortality was lower for patients experiencing EBV infection (2/33 (6%) vs 8/28 (29%), OR 0.2; 95% CI 0.05-0.9, P=0.03). The EBV protocol proved feasible and resulted in faster initiation of pre-emptive therapy, the diagnosis in an earlier stage of EBV disease, and decreased EBV-related mortality.Bone Marrow Transplantation advance online publication, 10 June 2013; doi:10.1038/bmt.2013.84.

Published
2013

46. Circulating galectin-3 in infections and non-infectious inflammatory diseases.

Author

Oever, J. ten, Giamarellos-Bourboulis, E.J., Veerdonk, F.L. van de, Stelma, F.F., Simon, A., Janssen, M, Johnson, M., Pachot, A., Kullberg, B.J., Joosten, L.A.B., Netea, M.G., Oever, J. ten, Giamarellos-Bourboulis, E.J., Veerdonk, F.L. van de, Stelma, F.F., Simon, A., Janssen, M, Johnson, M., Pachot, A., Kullberg, B.J., Joosten, L.A.B., and Netea, M.G.

Abstract

Item does not contain fulltext

Published
2013

47. Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome

Author

Prinsen, H., Vries, I.J.M. de, Torensma, R., Pots, J.M., Mulder, S.F., van Herpen, C.M., Elving, L.D., Bleijenberg, G., Stelma, F.F., Laarhoven, H.W.M. van, Prinsen, H., Vries, I.J.M. de, Torensma, R., Pots, J.M., Mulder, S.F., van Herpen, C.M., Elving, L.D., Bleijenberg, G., Stelma, F.F., and Laarhoven, H.W.M. van

Abstract

Contains fulltext : 108175.pdf (publisher's version ) (Open Access), BACKGROUND: Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon influenza vaccination in CFS patients and healthy controls. RESULTS: Identical antibody titers were observed in CFS patients and healthy controls. Patients and controls demonstrated similar seroprotection rates against all three virus-strains of the influenza vaccine, both pre- and post-vaccination. Functional T cell reactivity was observed in both CFS patients and healthy controls. CFS patients showed a non-significant, numerically lower cellular proliferation at baseline compared to controls. Vaccination induced a significant increase in cellular proliferation in CFS patients, but not in healthy controls. Cytokine production and the number of regulatory T cells were comparable in patients and controls. CONCLUSIONS: The humoral and cellular immune responses upon influenza vaccination were comparable in CFS patients and healthy controls. Putative aberrations in immune responses in CFS patients were not evident for immunity towards influenza. Standard seasonal influenza vaccination is thus justified and, when indicated, should be recommended for patients suffering from CFS.

Published
2012

48. The first locally acquired human infection of Echinococcus multilocularis in The Netherlands.

Author

Dommelen, L. van, Stoot, J.H., Cappendijk, V.C., Abdul Hamid, M.A., Stelma, F.F., Kortbeek, L.M., Giessen, J. van der, Oude Lashof, A.M.L., Dommelen, L. van, Stoot, J.H., Cappendijk, V.C., Abdul Hamid, M.A., Stelma, F.F., Kortbeek, L.M., Giessen, J. van der, and Oude Lashof, A.M.L.

Abstract

1 mei 2012, Item does not contain fulltext, In the northern part of Western Europe, Echinococcus multilocularis is primarily detected in and spreading among foxes. The present case marks E. multilocularis as an emerging pathogen for humans, as it describes the first human case of probably locally acquired E. multilocularis in The Netherlands, with various interesting clinical aspects.

Published
2012

49. Impact of bacterial colonization on exhaled inflammatory markers in wheezing preschool children

Author

van de Kant, K.D., Klaassen, E.M., van Aerde, K.J., Damoiseaux, J., Bruggeman, C.A., Stelma, F.F., Stobberingh, E.E., Muris, J.W.M., Jobsis, Q., van Schayck, O.C., Dompeling, E., van de Kant, K.D., Klaassen, E.M., van Aerde, K.J., Damoiseaux, J., Bruggeman, C.A., Stelma, F.F., Stobberingh, E.E., Muris, J.W.M., Jobsis, Q., van Schayck, O.C., and Dompeling, E.

Abstract

Item does not contain fulltext, Wheeze is a common symptom in preschool children. The role of bacteria, regulatory T (T(reg)) cells and their association with airway inflammation in preschool wheeze is largely unknown. We evaluated inflammatory markers in exhaled breath condensate (EBC), bacterial colonization and circulating T(reg) cells in preschool children with and without recurrent wheeze. We recruited 252 children (aged two to four years) with (N = 202) and without (N = 50) recurrent wheeze. EBC was collected using an efficient closed glass condenser. Inflammatory markers in EBC (Interleukin(IL)-2, IL-4, IL-8, IL-10, IL-13) were assessed using multiplex immunoassay. Nasal and throat swabs were analysed for presence of Streptococcus pneumoniae, Haemophilus (para)influenzae and Staphylococcus aureus. Proportions of T(reg) cells (CD4(+)CD25(high)CD127(-)) were quantified by flow cytometry. Recurrent wheezing children had elevated EBC levels of IL-2, IL-4, IL-10 and IL-13 compared to non-wheezers (odds ratio (95% confidence interval): 1.67 (1.23-2.27): 1.58 (1.15-2.18): 1.47 (1.14-1.90): 1.55 (1.16-2.06), p <0.05, respectively). Bacteria were frequently present in children with and without wheeze, with no difference in prevalence (16-52% versus 16-50%, respectively). Moreover, the proportion of T(reg) cells did not differ between both groups. Wheezing children with bacterial colonization did not significantly differ in exhaled levels of inflammatory markers or proportion of T(reg) cells compared to wheezing children without colonization. The analysis of EBC might serve as a helpful non-invasive tool to early assess airway inflammation in wheezing children. The various elevated exhaled inflammatory markers indicate increased airway inflammation in wheezing preschool children. In the presence of wheeze, we found no evidence for bacterial induced airway inflammation.

Published
2012

50. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010

Author

Meijer, F.J.A., Jonges, M., Abbink, F., Ang, W., Beek, J., Beersma, M., Bloembergen, P., Boucher, C., Claas, E., Donker, G., Gageldonk-Lafeber, R. van, Isken, L., Jong, A. de, Kroes, A., Leenders, S., Lubben, M. van der, Mascini, E., Niesters, B., Oosterheert, J.J., Osterhaus, A., Riesmeijer, R., Riezebos-Brilman, A., Schutten, M., Sebens, F., Stelma, F.F., Swaan, C., Timen, A., Veen, A., Vries, E. de, Wierik, M. te, Koopmans, M., Meijer, F.J.A., Jonges, M., Abbink, F., Ang, W., Beek, J., Beersma, M., Bloembergen, P., Boucher, C., Claas, E., Donker, G., Gageldonk-Lafeber, R. van, Isken, L., Jong, A. de, Kroes, A., Leenders, S., Lubben, M. van der, Mascini, E., Niesters, B., Oosterheert, J.J., Osterhaus, A., Riesmeijer, R., Riezebos-Brilman, A., Schutten, M., Sebens, F., Stelma, F.F., Swaan, C., Timen, A., Veen, A., Vries, E. de, Wierik, M. te, and Koopmans, M.

Abstract

Item does not contain fulltext, Enhanced surveillance of infections due to the pandemic A(H1N1) influenza virus, which included monitoring for antiviral resistance, was carried out in the Netherlands from late April 2009 through late May 2010. More than 1100 instances of infection with the pandemic A(H1N1) influenza virus from 2009 and 2010 [A(H1N1) 2009] distributed across this period were analyzed. Of these, 19 cases of oseltamivir-resistant virus harboring the H275Y mutation in the neuraminidase (NA) were detected. The mean 50% inhibitory concentration (IC50) levels for oseltamivir- and zanamivir-susceptible A(H1N1) 2009 viruses were 1.4-fold and 2-fold, respectively, lower than for the seasonal A(H1N1) influenza viruses from 2007/2008; for oseltamivir-resistant A(H1N1) 2009 virus the IC50 was 2.9-fold lower. Eighteen of the 19 patients with oseltamivir-resistant virus showed prolonged shedding of the virus and developed resistance while on oseltamivir therapy. Sixteen of these 18 patients had an immunodeficiency, of whom 11 had a hematologic disorder. The two other patients had another underlying disease. Six of the patients who had an underlying disease died; of these, five had received cytostatic or immunosuppressive therapy. No indications for onward transmission of resistant viruses were found. This study showed that the main association for the emergence of cases of oseltamivir-resistant A(H1N1) 2009 virus was receiving antiviral therapy and having drug-induced immunosuppression or an hematologic disorder. Except for a single case of a resistant virus not linked to oseltamivir therapy, the absence of detection of resistant variants in community specimens and in specimens from contacts of cases with resistant virus suggested that the spread of resistant A(H1N1) 2009 virus was limited. Containment may have been the cumulative result of impaired NA function, successful isolation of the patients, and prophylactic measures to limit exposure.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results